Transplantation of major ABO-incompatible bone marrow depleted of red cells by hydroxyethyl starch.
23 bone marrow transplant recipients whose donors where major ABO-incompatible received marrow depleted of red cells prior to infusion utilizing gravity sedimentation in hydroxyethyl starch. The in vitro red cell-depletion procedure effectively removed 97.8% (mean) of the red cells from the harvested marrows and preserved 86.8% of the nucleated cells and 98.2% of the CFU-C activity in 25.4% of the original volume. All recipients had a significant quantity of isohemagglutinins of both IgM and IgG classes demonstrable in their serum at the time of the marrow infusion. Patients were premedicated and well-hydrated prior to the infusion and tolerated the infusion well. These patients demonstrated bone marrow engraftment at the same rate as did those patients whose marrow donors were either ABO-identical or minor ABO-incompatible. There was no difference in the incidence of or time to development of graft versus host disease, the incidence of graft rejection, or patient survival among the groups. Recipients of red cell-depleted major ABO-incompatible bone marrow transplants demonstrated production of donor-type red cells somewhat later and required slightly more red cell transfusion support that did the other groups of recipients. This red cell-depletion technique is safe and effective in the management of major ABO-incompatible bone marrow transplantation.
P I
PI
Warkentin
J M
JM
Hilden
J H
JH
Kersey
N K
NK
Ramsay
J
J
McCullough
D000017:ABO Blood-Group System / Q000276:immunology*; D000293:Adolescent; D000328:Adult; D001663:Bilirubin / Q000097:blood; D001787:Blood Group Incompatibility / Q000097:blood* / Q000209:etiology; D001854:Bone Marrow Cells; D016026:Bone Marrow Transplantation; D002469:Cell Separation / Q000379:methods*; D002648:Child; D002675:Child, Preschool; D004906:Erythrocyte Count; D004912:Erythrocytes / Q000187:drug effects; D006386:Hemagglutination Tests; D006456:Hemoglobinuria / Q000209:etiology; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D007223:Infant; D007518:Isoantibodies / Q000032:analysis; D013213:Starch / Q000031:analogs & derivatives; D014184:Transplantation, Homologous / Q000009:adverse effects
D000017:ABO Blood-Group System; D006895:Hydroxyethyl Starch Derivatives; D007518:Isoantibodies; D013213:Starch; D001663:Bilirubin